Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma

Predictive biomarkers of response to immune checkpoint-based therapies (ICI) remain a critically unmet need in the management of advanced renal cell carcinoma (RCC). The complex interplay of the tumour microenvironment (TME) and the circulating immune response has proven to be challenging to deciphe...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 14; no. 1; p. 8603
Main Authors Soleimani, Maryam, Thi, Marisa, Janfaza, Sajjad, Ozcan, Gizem, Mazurek, Sylwia, Ozgun, Guliz, Maurice-Dror, Corinne, Eigl, Bernhard, Chi, Kim, Kollmannsberger, Christian, Nappi, Lucia
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 13.04.2024
Nature Publishing Group
Nature Portfolio
Subjects
631/67/1857
692/4028/67/589/1588/1351
692/53/2423
Biomarkers
Consent
Defence mechanisms
Extracellular vesicles
Gene expression
Gene regulation
Hemoglobin
Humanities and Social Sciences
Immune checkpoint
Immune response
Immunity
Immunomodulation
Immunotherapy
Kidney cancer
Kinases
Medical prognosis
Metastases
Metastasis
MicroRNAs
miRNA
multidisciplinary
Neoplasms
Patients
Plasma
Post-transcription
Renal cell carcinoma
Science
Science (multidisciplinary)
Statistical analysis
Tumor microenvironment
Online AccessGet full text

Cover

More Information
Summary:Predictive biomarkers of response to immune checkpoint-based therapies (ICI) remain a critically unmet need in the management of advanced renal cell carcinoma (RCC). The complex interplay of the tumour microenvironment (TME) and the circulating immune response has proven to be challenging to decipher. MicroRNAs have gained increasing attention for their role in post-transcriptional gene expression regulation, particularly because they can have immunomodulatory properties. We evaluated the presence of immune-specific extracellular vesicle (EV) microRNAs in the plasma of patients with metastatic RCC (mRCC) prior to initiation of ICI. We found significantly lower levels of microRNA155-3p (miR155) in responders to ICI, when compared to non-responders. This microRNA has unique immunomodulatory properties, thus providing potential biological rationale for our findings. Our results support further work in exploring microRNAs as potential biomarkers of response to immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-59337-4